Peptide Reconstitution Reference: 10 Peptides, Dosage Tables and Protocols

BPC-157

Calculate a BPC-157 dose in the interactive tool →

BPC-157 Dosage Reference Table

Common reconstitution for a 5mg vial. Use the BPC-157 calculator above to generate your specific settings.

Mechanism of Action

BPC-157 is thought to upregulate growth hormone receptor expression and promote angiogenesis through the VEGF (vascular endothelial growth factor) signaling pathway. It also modulates the NO system (nitric oxide), influences tendon-bone healing via activation of the FAK-paxillin pathway, and exhibits a cytoprotective effect on gastric mucosa. Animal studies show systemic activity after both subcutaneous and oral administration.

Angiogenesis and Vascular Remodeling

One of the most extensively documented mechanisms of BPC-157 in preclinical models is its promotion of angiogenesis—the formation of new vessels from existing ones. BPC-157 upregulates expression of VEGF and its receptor VEGFR2 in endothelial cells, driving neovascularization at injury sites. This is especially important in tendon and ligament repair models, where poor blood supply is a major limiting factor in healing kinetics.

Furthermore, BPC-157 activates the FAK-paxillin pathway—a focal adhesion kinase signaling cascade that regulates cytoskeletal reorganization and cell migration. In fibroblast cultures this leads to accelerated migration toward wound edges, a prerequisite for connective tissue repair.

BPC-157 and the Nitric Oxide (NO) System

BPC-157's modulation of the nitric oxide synthase (NOS) system is a unique and well-defined axis. In vascular-injury and shock animal models, BPC-157 demonstrates the ability to activate and counteract NO overproduction depending on the pathological context—a phenomenon described as "NO system salvage". Specifically, BPC-157 appears to restore NOS homeostasis in rats after L-NAME (a NOS inhibitor) or L-arginine (a NOS substrate) challenge, normalizing blood pressure and vascular tone.

BPC-157 Reconstitution Steps

Storage and Safety Notes

FAQ

What if the reconstituted BPC-157 solution is cloudy?

A properly reconstituted BPC-157 solution should be clear and colorless. Cloudiness indicates one of three situations: (1) incomplete dissolution—allow more time with gentle rotation; (2) peptide aggregation due to improper reconstitution technique (rapid injection, shaking, or incorrect solvent temperature); (3) microbial contamination. If cloudiness does not clear after 10-15 minutes of gentle rolling, or if visible particles remain, the vial should be discarded. Do not filter through a standard syringe filter unless the membrane is validated for this molecular-weight peptide, as significant loss may occur.

Can BPC-157 and TB-500 be mixed in the same syringe?

In preclinical studies, BPC-157 and TB-500 (a thymosin beta-4 analog) are sometimes co-administered in combination protocols to study synergistic tissue-repair effects. Physicochemically, both peptides are stable in BAC water at physiological pH, and no documented incompatibility exists in the published literature. However, mixing two peptides in one syringe introduces compounding variables that complicate dose precision and outcome interpretation. If co-administration is required by the study protocol, drawing from each vial separately into the same syringe immediately before use is methodologically superior to a pre-mixed vial.

Tirzepatide

Calculate a Tirzepatide dose in the interactive tool →

Tirzepatide Dosage Reference Table

Common reconstitution for a 5mg vial. Use the Tirzepatide calculator above to generate your specific settings.

Mechanism of Action

As a dual agonist, Tirzepatide acts on both the GIP receptor and the GLP-1 receptor—two key incretin hormone pathways involved in postprandial insulin secretion and glucagon suppression. By co-activating both receptors it produces a synergistic reduction in HbA1c and body weight beyond what a single-receptor GLP-1 agonist can achieve. The compound also delays gastric emptying, reduces appetite via central hypothalamic pathways, and improves insulin sensitivity in peripheral tissues through mechanisms that may involve adipose tissue remodeling.

Incretin Mimicry Synergy and Gastric Emptying

Incretins are hormones secreted by the gut after meals that enhance glucose-stimulated insulin secretion from pancreatic beta cells. GIP is released mainly by K cells in the duodenum and proximal jejunum, while GLP-1 is secreted by L cells concentrated in the ileum and colon. Under physiological conditions both act in a glucose-dependent manner—their insulinotropic effect is attenuated when blood glucose is normal, giving a better low-blood-sugar risk profile than sulfonylureas. Tirzepatide's dual-receptor activation produces a synergistic metabolic response: GLP-1R agonism drives nutrient-stimulated insulin secretion, glucagon suppression and delayed gastric emptying, while GIP receptor co-activation further enhances the insulin-secretory response and contributes distinct adipokine effects at the adipocyte level via GIPR-mediated cAMP signaling.

Delayed Gastric Emptying and Appetite Suppression

GLP-1R and GIPR are both expressed in the hypothalamus and brainstem—the centers for appetite regulation and energy homeostasis. GLP-1R activation in the arcuate nucleus and nucleus of the solitary tract inhibits orexigenic neuropeptide Y (NPY) and agouti-related peptide (AgRP) signaling while enhancing anorexigenic POMC/CART pathways. The resulting reduction in caloric intake, combined with slowed gastric emptying (prolonging satiety signals), together explains the significant weight loss observed in the SURMOUNT and SURPASS trial series. The GIPR component adds a further layer via GIPR expression in central dopaminergic reward circuits, potentially regulating food-reward valuation independent of satiety— a mechanistic distinction from pure GLP-1R agonists such as Semaglutide.

Tirzepatide Reconstitution Steps

Storage and Safety Notes

FAQ

How long does reconstituted Tirzepatide retain potency?

Reconstituted Tirzepatide stored in bacteriostatic water (0.9% benzyl alcohol) at 2-8°C maintains research-grade stability for up to 28 days. Beyond this window, hydrolytic degradation of the peptide backbone and potential oxidation of the fatty acid linker accumulate to levels that may compromise dose accuracy and bioactivity. Degradation has no reliable visual indicator—the solution remains clear throughout. For time-sensitive study protocols, prepare the minimum volume needed for each study period rather than drawing from a single large-volume reconstitution batch.

Can Tirzepatide be pre-filled in a syringe for research?

Pre-filling Tirzepatide solution in a syringe is methodologically ill-advised. First, the air-liquid interface inside a pre-filled syringe provides a persistent surface for interface-induced peptide aggregation— particularly relevant for large lipopeptides. Second, plastic syringe barrels (typically polypropylene) adsorb peptide from solution, gradually reducing the delivered dose over hours to days, with a stronger effect at lower concentrations. If the protocol absolutely requires a pre-filled formulation, use a glass syringe, minimize dead volume, store horizontally at 2-8°C, and discard any formulation older than 12 hours. A freshly drawn dose immediately before use remains the methodological gold standard.

Semaglutide

Calculate a Semaglutide dose in the interactive tool →

Semaglutide Dosage Reference Table

Common reconstitution for a 5mg vial. Use the Semaglutide calculator above to generate your specific settings.

Mechanism of Action

Semaglutide binds and activates the GLP-1 receptor, stimulating glucose-dependent insulin secretion and suppressing glucagon release from pancreatic alpha cells. Its extended half-life is conferred by a C18 fatty diacid moiety attached to the lysine at position 26 (via a hydrophilic spacer), promoting non-covalent albumin binding and reducing renal clearance. Centrally, semaglutide crosses the blood-brain barrier to act on hypothalamic and brainstem circuits that regulate appetite and energy homeostasis, reducing caloric intake and producing significant weight loss in preclinical and clinical models.

The Incretin System and GLP-1 Receptor Signaling

Semaglutide exerts its primary effect by binding and activating the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor (GPCR) expressed in the pancreas, gastrointestinal tract, heart, kidney, and central nervous system. Under normal physiology, endogenous GLP-1 is secreted by intestinal L cells in response to nutrient intake, acting as an incretin hormone—enhancing glucose-dependent insulin secretion from pancreatic beta cells and suppressing glucagon release from alpha cells. This glucose dependence is pharmacologically important: insulin secretion is amplified only when postprandial blood glucose is elevated, markedly lowering the hypoglycemia risk associated with receptor activation.

Central Nervous System: the Arcuate Nucleus of the Hypothalamus

Beyond peripheral effects, semaglutide crosses the blood-brain barrier—particularly at the circumventricular organs where the barrier is fenestrated—acting directly on GLP-1R in the arcuate nucleus (ARC) of the hypothalamus. Within the ARC, GLP-1R activation inhibits orexigenic neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons while activating anorexigenic proopiomelanocortin (POMC) neurons. The net effect is reduced caloric intake via central appetite suppression. Brainstem GLP-1R signaling in the nucleus of the solitary tract (NTS) also integrates satiety signals from vagal afferents, further reducing food intake in rodent behavioral studies.

Semaglutide Reconstitution Steps

Storage and Safety Notes

FAQ

What if the reconstituted Semaglutide solution remains cloudy?

A properly reconstituted semaglutide solution should be clear to slightly opalescent—due to the amphiphilic nature of the fatty acid conjugation, very slight opalescence is acceptable. Persistent cloudiness, visible particles, or foam that does not dissipate after standing 5-10 minutes indicates one of three problems: (1) aggregation caused by mechanical agitation during or after reconstitution; (2) thermal shock from injecting cold BAC water into a cold peptide vial—both should be at room temperature before reconstitution; or (3) solvent incompatibility—only bacteriostatic water or sterile saline should be used. Vials that are cloudy or contain particles should be discarded, because aggregated peptide cannot be reliably disaggregated by further mixing and will yield inconsistent dose data.

How does Semaglutide's ~7-day half-life affect study dosing intervals?

Semaglutide's terminal elimination half-life of about 165-168 hours (~7 days) has far-reaching implications for study design. First, steady-state plasma concentrations require roughly 4-5 half-lives to be reached—meaning 4 to 5 weeks of weekly dosing are needed to establish pharmacokinetic equilibrium. Researchers should not interpret pharmacodynamic effects observed in the first 3-4 weeks as representative of the steady-state response. Second, the long half-life demands an extended washout in crossover or sequential dose designs: a minimum 5-week washout (5 × 7 days = 35 days) is needed to bring plasma levels below 5% of peak. Third, because steady-state accumulation develops gradually, the pronounced dose-dependent gastrointestinal effects at initiation diminish over time, accompanied by receptor desensitization and central adaptation—a time course that must be accounted for in tolerability assessment.

TB-500

Calculate a TB-500 dose in the interactive tool →

TB-500 Dosage Reference Table

Common reconstitution for a 5mg vial. Use the TB-500 calculator above to generate your specific settings.

Mechanism of Action

TB-500 sequesters G-actin monomers through its LKKTET actin-binding domain, promoting actin polymerization—a mechanism that facilitates cell migration and wound healing. It stimulates angiogenesis by upregulating VEGF and activates matrix metalloproteinases (MMPs) involved in extracellular matrix remodeling. Additionally, TB-500 exhibits anti-inflammatory properties in animal injury models by downregulating inflammatory cytokines including IL-1β and TNF-α.

Actin-Binding Domain and G-Actin Sequestration

TB-500's primary molecular function is high-affinity binding of monomeric globular actin (G-actin) via its LKKTET motif. The intracellular G-actin to filamentous F-actin ratio determines whether a cell remains quiescent or enters a migratory state. By binding and maintaining a large pool of polymerization-competent G-actin, TB-500 primes the cell at the threshold for rapid migration— enabling rapid deployment of lamellipodia and filopodia upon receipt of a migration signal. This mechanism lies downstream of the Rho GTPase signaling pathway (particularly Rac1 and Cdc42), which coordinates directed cell migration during wound closure and tissue remodeling.

Angiogenesis and Endothelial Cell Differentiation

In endothelial cells, TB-500 promotes angiogenesis through two parallel pathways. First, actin-dependent endothelial migration drives the sprouting phase of neovascularization; in Matrigel assays, TB-500-treated cells form tubular structures at a significantly higher rate than controls. Second, TB-500 upregulates VEGF and its receptor VEGFR2, amplifying the angiogenic signaling cascade. The resulting increase in capillary density at injury sites restores oxygen and nutrient supply— the rate-limiting step in healing avascular or poorly vascularized tissues such as tendon, cartilage, and myocardium. At the same time, TB-500 stimulates production of extracellular matrix components (especially type I and III collagen) by activating fibroblasts at the repair site, and creates an anti-inflammatory microenvironment favorable to orderly tissue regeneration rather than fibrotic scarring by suppressing the NF-κB pathway and downregulating pro-inflammatory cytokines (IL-1β, IL-6, TNF-α).

TB-500 Reconstitution Steps

Storage and Safety Notes

FAQ

Can TB-500 and BPC-157 be reconstituted in the same vial?

Although TB-500 and BPC-157 are both stable in BAC water, with no documented direct chemical incompatibility, co-reconstituting them in the same vial is generally not recommended in a strict research setting, for the following reasons: First, a mixed-vial formulation makes independent dose titration impossible—if one compound behaves unexpectedly, it cannot be adjusted without affecting the other. Second, the long-term stability of the combined solution has not been formally characterized; peptide-peptide interactions (electrostatic, hydrophobic, or aggregation-promoting) cannot be excluded without specific stability testing. Third, regulatory and publication standards for preclinical research require clearly separated, independently verifiable dose records. The methodologically sound approach is to reconstitute each in its own vial and draw sequentially into the same syringe immediately before use—allowing both independent concentration control and co-delivery.

Why is TB-500 typically dosed higher than other peptides?

TB-500's higher per-dose amounts in animal studies arise from its mechanism rather than lower potency. Because TB-500 acts by maintaining an elevated intracellular G-actin pool throughout the tissue system— rather than triggering a cascade from a single receptor like GPCR-targeted peptides—a proportionally higher effective concentration is required to shift the global G-actin:F-actin balance. The receptor agonist Ipamorelin and repair peptide BPC-157 produce systemic effects from mcg-scale doses because signal amplification through second-messenger cascades multiplies the initial binding event. G-actin sequestration has no equivalent amplification step; the peptide must be present in sufficient quantity to occupy a meaningful fraction of the available actin pool. The TB-500 dosage table above (computed from your specific vial size and BAC water volume) helps convert this higher absolute dose into precise syringe units.

Ipamorelin

Calculate a Ipamorelin dose in the interactive tool →

Ipamorelin Dosage Reference Table

Common reconstitution for a 2mg vial. Use the Ipamorelin calculator above to generate your specific settings.

Mechanism of Action

Ipamorelin acts as a selective growth hormone-releasing peptide (ghrelin) mimetic, binding the GHS-R1a receptor on pituitary somatotrophs and hypothalamic neurons with high affinity. This binding triggers pulsatile GH release via a Gq/11 protein-coupled inositol phosphate signaling pathway, closely mimicking the endogenous ghrelin-driven GH secretion pattern. Critically, at study-relevant doses Ipamorelin does not activate the adrenocorticotropic hormone (ACTH) axis nor stimulate cortisol or prolactin release— a selectivity feature that distinguishes it from GHRP-2 and GHRP-6. The resulting GH pulses stimulate hepatic IGF-1 production, driving anabolic and lipolytic effects in peripheral tissues.

Selective Ghrelin Mimicry: GHS-R1a Agonism

Ipamorelin's primary mechanism is agonism at the growth hormone secretagogue receptor 1a (GHS-R1a), a Gq/11-coupled receptor expressed most densely on anterior pituitary somatotrophs and hypothalamic arcuate nucleus neurons. GHS-R1a is the native receptor for ghrelin, a 28-amino-acid orexigenic peptide produced mainly by the stomach. Ipamorelin mimics ghrelin's receptor-activation conformation but lacks ghrelin's octanoyl fatty acid modification—the structural basis for ghrelin's off-target effects on appetite and cortisol.

High Selectivity: Why ACTH, Cortisol, and Prolactin Are Spared

The definitive pharmacological feature of Ipamorelin versus earlier GHRPs is its superior selectivity for GHS-R1a-mediated GH release. GHRP-6 and GHRP-2 activate not only GHS-R1a but also interact with non-specific receptors on corticotrophs (triggering ACTH and cortisol release) and on lactotrophs (triggering prolactin release). These off-target activations complicate data interpretation and introduce confounding variables into GH-axis studies. Ipamorelin's structural geometry—particularly its D-2-Nal and D-Phe residues— confers shape complementarity to GHS-R1a while producing minimal activation of ACTH, cortisol, or prolactin pathways at doses that yield maximal GH release. This selectivity makes Ipamorelin the preferred tool when a researcher needs an independent readout of somatotroph function.

Ipamorelin Reconstitution Steps

Storage and Safety Notes

FAQ

Does Ipamorelin cause hunger like GHRP-6?

Significantly less. GHRP-6's orexigenic (appetite-stimulating) effect is a well-documented off-target consequence of its interaction with non-GHS-R1a receptors, including ghrelin receptor isoforms expressed in hypothalamic feeding circuits and vagal afferents. GHRP-6's appetite stimulation is often strong enough to be a confounder in body-composition studies. Ipamorelin's superior selectivity for the pituitary GHS-R1a subtype, combined with its lack of fatty acid modification (which mediates most of ghrelin's orexigenic signaling), leads to a substantial reduction in hunger signals. In animal studies at GH-equivalent doses, Ipamorelin's effect on food intake is negligible, making it a cleaner research tool for studies that do not target appetite as a variable.

Why is Ipamorelin often combined with CJC-1295 in research?

The combination targets two complementary nodes of the GH secretory axis, producing a synergistic effect greater than either compound alone. Ipamorelin acts on the GHS-R1a receptor (the ghrelin receptor) on somatotrophs, triggering pulsatile GH release via calcium-dependent exocytosis. CJC-1295 (with DAC) acts on the GHRH receptor on the same somatotrophs, enhancing GH pulse amplitude via the cAMP-PKA pathway. The two synergize on orthogonal axes: amplitude × frequency = total GH output. Rodent studies combining a GHRH analog with a GHRP have shown GH area-under-the-curve (AUC) values 2-10× those of either compound alone at equivalent doses, depending on timing and dose.

CJC-1295

Calculate a CJC-1295 dose in the interactive tool →

CJC-1295 Dosage Reference Table

Common reconstitution for a 2mg vial. Use the CJC-1295 calculator above to generate your specific settings.

Mechanism of Action

CJC-1295 (with DAC) binds the GHRH receptor in the anterior pituitary, stimulating synthesis and release of growth hormone. The DAC modification achieves irreversible binding to serum albumin via a reactive lysine residue (bioconjugation), protecting the peptide from enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and extending its half-life to 6-8 days. This produces a sustained elevation of baseline GH and IGF-1 levels, in contrast to the pulsatile release pattern induced by unmodified GHRH or Ipamorelin.

GHRH Receptor Agonism and Somatotroph Stimulation

CJC-1295 is a potent agonist of the GHRH receptor on anterior pituitary somatotrophs. The GHRH receptor (GHRHR) is a class B GPCR that, upon agonist binding, couples to the Gαs protein and activates adenylate cyclase, raising intracellular cAMP. Elevated cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB (cAMP response element-binding protein). CREB activation drives transcription of the GH1 gene and stimulates synthesis and secretion of growth hormone from somatotroph secretory granules.

GH Pulse Amplitude and the GH-Axis Feedback Loop

CJC-1295's primary pharmacodynamic effect is to amplify GH pulse amplitude—the peak GH concentration released per secretory event—rather than increase GH pulse frequency. In rodent studies using pulsatile GH modeling, GHRH analogs consistently increase GH peak height while preserving pulse frequency relatively unchanged. This amplitude-centric mechanism makes CJC-1295 pharmacologically complementary to growth hormone secretagogues (GHRPs) such as Ipamorelin, which primarily modulate pulse frequency via the independent GHS-R1a receptor. GH secretion is under dual hypothalamic control: GHRH (stimulatory) and somatostatin (inhibitory). CJC-1295 operates within this feedback network—its GH-releasing effect is attenuated during periods of high somatostatin tone (physiologically occurring postprandially and under stress), so its GH response is most pronounced in somatostatin troughs (fasting, resting states).

CJC-1295 Reconstitution Steps

Storage and Safety Notes

FAQ

Can CJC-1295 and Ipamorelin be mixed in the same syringe for research?

Yes—in preclinical co-administration protocols, mixing CJC-1295 (particularly the No DAC / Mod GRF 1-29 form) and Ipamorelin in the same syringe immediately before use is standard practice and is physicochemically acceptable. Both peptides are stable in BAC water at refrigerated temperatures, and no documented incompatibility or co-precipitation event exists between them in published preclinical literature. The key operational rule is "use immediately after drawing": the combined solution should not be pre-mixed and stored, because the long-term stability of combined formulations has not been formally characterized. The same logic applies to the DAC form— draw from the two vials into a single syringe immediately before use; do not pre-mix vials. The advantage of same-syringe co-administration in research is precise temporal co-delivery, maximizing synergistic GH release.

Which version should I choose for steady-state GH studies?

For studies of steady-state IGF-1 elevation and sustained GH-axis stimulation—protocols examining long-term metabolic, anabolic, or bone-density effects— CJC-1295 with DAC is the appropriate choice. Its 6-8 day half-life produces a sustained GH "leak", maintaining elevated IGF-1 with once-weekly dosing, creating a pharmacokinetic steady baseline for multi-week studies. For studies of GH pulse dynamics, secretory kinetics, or the physiological consequences of pulsatile GH release— including episodic IGF-1 bursts, hepatic GH receptor pulsatility, or sleep-stage GH coupling—CJC-1295 No DAC (Mod GRF 1-29) is the correct tool. Its 30-minute half-life lets the researcher time discrete, physiological GH pulses. CJC-1295 (with DAC) and CJC-1295 No DAC (Mod GRF 1-29) are distinct research compounds with opposite pharmacokinetic profiles. Mislabeling or interchanging them would fundamentally alter study results. Verify peptide identity by requesting a Certificate of Analysis (CoA) with HPLC purity and mass-spectrometry confirmation.

Melanotan II

Calculate a Melanotan II dose in the interactive tool →

Melanotan II Dosage Reference Table

Common reconstitution for a 10mg vial. Use the Melanotan II calculator above to generate your specific settings.

Mechanism of Action

Melanotan II binds melanocortin receptors with high affinity for MC1R, MC3R, MC4R, and MC5R. Activation of MC1R in melanocytes triggers the adenylate cyclase signaling pathway, raising cAMP and stimulating eumelanin synthesis. MC4R activation in the hypothalamus regulates appetite and energy homeostasis, while MC3R and MC4R activity are linked to sexual function and arousal pathways. Its cyclic structure (formed via disulfide bonds) confers higher receptor affinity and metabolic stability than linear α-MSH.

MC1R: the Melanogenesis Pathway

MT-2's most extensively studied activity is at the melanocortin-1 receptor (MC1R), expressed mainly on epidermal melanocytes. MC1R is a Gs-coupled receptor; agonist binding activates adenylate cyclase, raising intracellular cAMP. The cAMP surge activates protein kinase A (PKA), which in turn phosphorylates CREB (cAMP response element-binding protein). CREB drives expression of MITF (microphthalmia-associated transcription factor), the master regulator of melanogenesis, upregulating tyrosinase, TRP-1, and TRP-2—the rate-limiting enzymes of eumelanin synthesis—leading to the observed pigment darkening in MT-2-treated animal models.

MC4R: Central Pathways in Research Models

MT-2 shows notable agonist activity at the melanocortin-4 receptor (MC4R), widely distributed in the central nervous system—particularly the hypothalamic paraventricular nucleus and limbic structures. MC4R activation inhibits neuropeptide Y (NPY) and agouti-related peptide (AgRP) signaling, producing dose-dependent reductions in food intake and body weight in rodent models. In limbic and spinal cord circuits, MC4R and MC3R activation modulate dopaminergic reward pathways and sexual-motivation behavior—observations that drove the development of PT-141 (bremelanotide) to isolate this central activity profile.

Melanotan II Reconstitution Steps

Storage and Safety Notes

FAQ

Why does Melanotan II cause nausea in some research models?

Nausea in MT-2-treated animal models is attributed mainly to activation of MC4R and MC3R in the area postrema (AP) and nucleus of the solitary tract (NTS)—brainstem structures that integrate emetic signals and lie outside the blood-brain barrier, making them directly accessible to circulating peptide. The area postrema acts as the brain's chemoreceptor trigger zone; melanocortin receptor activation there triggers the same downstream signaling pathways as emetic stimuli acting via 5-HT3 and D2 receptors. Dose-dependent nausea in MT-2 research models is more pronounced at higher concentrations and during loading phases. Titrating from a lower starting concentration (supported by the 3ml BAC water preparation) is the standard methodological path to determine the nausea threshold.

Does Melanotan II affect existing moles or freckles in research?

Existing pigmented lesions—including moles and freckles—contain a higher baseline concentration of melanocytes with their melanogenic machinery already pre-activated. Because these cells already express elevated levels of MITF, tyrosinase, and melanogenic precursor enzymes, MT-2's stimulation of MC1R produces a proportionally amplified pigment response in existing lesions compared with surrounding normal skin. In rodent models that induce nevi, MT-2 administration consistently causes measurable darkening of pre-existing lesions at lower concentrations than required for equivalent darkening of unaffected skin. Baseline lesion mapping and photographic documentation are recommended in any MT-2 melanogenesis study design.

PT-141

Calculate a PT-141 dose in the interactive tool →

PT-141 Dosage Reference Table

Common reconstitution for a 10mg vial. Use the PT-141 calculator above to generate your specific settings.

Mechanism of Action

PT-141 is a non-selective melanocortin receptor agonist whose primary activity is at MC3R and MC4R in the hypothalamus and limbic system. Activation of these central pathways modulates dopaminergic and oxytocinergic neurotransmission in circuits related to sexual motivation and arousal. Unlike Melanotan II, PT-141 has lower affinity for MC1R and therefore weaker melanogenic effects. Its mechanism is independent of the nitric oxide and cGMP pathways, distinguishing it pharmacologically from phosphodiesterase inhibitors.

Melanocortin Receptor Agonist—Not a PDE5 Inhibitor

Traditional erectile-research compounds target the peripheral vasculature: PDE5 inhibitors block type 5 phosphodiesterase in penile smooth muscle, enhancing cGMP-mediated vasodilation driven by nitric oxide (NO) release during sexual stimulation. PT-141 acts by a completely different mechanism. It does not interact with the NO/cGMP axis, does not require concurrent stimulation as a prerequisite for activity, and produces no clinically significant vasodilation. Instead, it acts centrally—upstream of the vascular response—initiating a neural signaling cascade by activating melanocortin receptors in the brain, driving sexual arousal at the level of motivation and desire rather than merely vascular mechanics.

Hypothalamic MC4R and the Erection Neural Pathway

MC4R is expressed at high density in the hypothalamic paraventricular nucleus (PVN)—a key integration hub for autonomic, neuroendocrine, and behavioral output. PT-141 binding to hypothalamic MC4R activates Gαs-coupled signaling (adenylate cyclase → cAMP → PKA), driving oxytocinergic neurons in the PVN to release oxytocin into systemic circulation and via axonal projections to limbic structures including the medial preoptic area (MPOA). This oxytocin-mediated pathway modulates the dopamine reward circuit and activates descending spinal neural pathways that coordinate the erectile reflex arc—producing erection in male rodent models via a mechanism independent of peripheral vascular tone. The MPOA is a particularly important node: rodent lesion studies show MPOA integrity is required for PT-141's behavioral effects, confirming its centrally mediated mechanism.

PT-141 Reconstitution Steps

Storage and Safety Notes

FAQ

Does PT-141 cause tanning like Melanotan II in research models?

Melanotan II stimulates strong melanogenesis because it is a potent agonist of MC1R on melanocytes—the receptor subtype directly responsible for eumelanin synthesis and UV-independent skin darkening. PT-141's receptor selectivity profile is biased toward MC3R and MC4R, with significantly lower MC1R binding affinity than MT-II at the concentrations commonly used in arousal studies. In practice, PT-141's melanogenic effect is substantially weaker than equimolar MT-II. However, MC1R agonism is not entirely absent: at higher doses or in subjects with higher baseline MC1R expression, mild pigment changes—including mild transient skin darkening and increased freckling—have appeared in clinical trial data. In preclinical rodent models, coat-color pigmentation serves as a visible proxy for MC1R activation, and PT-141 produces markedly less darkening than MT-II at equivalent doses. Researchers designing pigmentation-controlled behavioral studies should include a selective MC1R antagonist as a control to exclude this confounder from result validity.

Why is nausea frequently reported in PT-141 research?

Nausea is the most frequently reported adverse event in PT-141 clinical trials and a major dose-limiting tolerability issue. Its mechanistic basis is MC4R activation in the brainstem area postrema (AP) and nucleus of the solitary tract (NTS)—structures that form the chemoreceptor trigger zone (CTZ) and integrate the emetic reflex signal. Because the blood-brain barrier is fenestrated at these periventricular brainstem structures, circulating PT-141 can contact them directly, meaning the same receptor population that drives hypothalamic arousal also activates the brainstem emetic circuit. This is a same-target, mechanism-based adverse effect—not a formulation artifact. In preclinical models the nausea response is dose-dependent and attenuates with repeated dosing, suggesting rapid MC4R tolerance at the brainstem level. Researchers modeling PT-141 tolerability should include nausea-related behaviors (pica, kaolin intake in rodents) as endpoints parallel to the primary arousal outcome, to provide a complete dose-tolerability profile at each experimental level.

AOD-9604

Calculate a AOD-9604 dose in the interactive tool →

AOD-9604 Dosage Reference Table

Common reconstitution for a 5mg vial. Use the AOD-9604 calculator above to generate your specific settings.

Mechanism of Action

AOD-9604 mimics the lipolytic fragment of human growth hormone—stimulating lipolysis (enzymatic breakdown of stored triglycerides in fat cells) and inhibiting adipogenesis (de novo conversion of non-fat dietary substrates into body fat)—without activating the classic GH receptor or IGF-1 axis. This "IGF-1-free advantage" is mechanistically crucial: full-length hGH stimulates IGF-1 production, driving insulin resistance, cellular proliferation, and fluid retention. AOD-9604 lacks hGH's receptor-binding domain (residues 1-176), does not trigger IGF-1 release, and does not alter blood glucose or insulin sensitivity—making it a cleaner metabolic research tool. Its lipolytic activity is believed to be mediated via β-3 adrenergic receptor signaling on adipocytes and a putative hGH fragment receptor pathway.

Stimulating Lipolysis: Adipocyte-Level Fat Breakdown

AOD-9604's primary metabolic activity is stimulating lipolysis—the enzymatic hydrolysis of stored triglycerides within fat cells into glycerol and free fatty acids to release energy substrates. In animal models, AOD-9604 activates β-3 adrenergic receptors on the adipocyte membrane, triggering a cAMP-mediated signaling cascade that activates hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL). These enzymes catalyze the sequential breakdown of triglycerides, diglycerides, and monoglycerides, releasing fatty acids into circulation for mitochondrial β-oxidation.

The IGF-1-Free Advantage: Why This Fragment Differs from Full-Length hGH

Full-length human growth hormone mainly activates the GH receptor via its receptor-binding domain in the N-terminal region (residues 1-176). This activation triggers hepatic IGF-1 production, driving the anabolic, anti-lipolytic, and diabetogenic effects associated with GH excess: insulin resistance, fluid retention, and increased soft-tissue growth and proliferative signaling. AOD-9604 contains only residues 177-191 plus an N-terminal tyrosine, completely lacking the receptor-binding domain. It does not bind the classic GH receptor, does not stimulate IGF-1 production, and does not alter blood glucose or insulin sensitivity in animal models at study-relevant doses. This separation of fat-metabolic activity from insulin-interfering activity is the core pharmacological rationale for AOD-9604 research.

AOD-9604 Reconstitution Steps

Storage and Safety Notes

FAQ

Is AOD-9604 the same as Fragment 177-191?

Yes, with one important modification. "hGH Fragment 177-191" refers to the original C-terminal peptide sequence of human growth hormone spanning residues 177 to 191. AOD-9604 is that fragment plus an N-terminal tyrosine (Tyr) residue, with the full sequence Tyr-hGH177-191. The tyrosine was added during development to improve the peptide's stability in biological media—the N-terminal amine is capped by the larger tyrosine side chain, reducing susceptibility to exopeptidase cleavage. In most research literature, AOD-9604 and hGH Frag 177-191 are used interchangeably, but strictly speaking AOD-9604 refers specifically to the stabilized form with the N-terminal tyrosine.

Why is fasting-state dosing so important for AOD-9604 lipolysis research?

In AOD-9604 animal model studies, dosing timing relative to the feeding/fasting cycle is consistently found to significantly modulate lipolytic output. In the fasting state, circulating insulin is low and lipolytic signaling is upregulated—fat cells are primed to release triglycerides, and AOD-9604's β-3 adrenergic stimulation produces amplified HSL and ATGL activation under these conditions. Dosing in the fed state—where elevated insulin actively suppresses HSL activity—attenuates the lipolytic response. Therefore, protocols designed to maximize lipolytic output must consistently control the fasting duration before dosing; rodent models typically use 4-6 hours. The fasting state at dosing is a key variable for AOD-9604 lipolysis research. Inconsistent fasting between experimental animals introduces a major confounder—protocols should standardize fasting duration, water access during fasting, and dosing time (relative to the animal's activity cycle) to obtain reproducible lipolysis data.

GHK-Cu

Calculate a GHK-Cu dose in the interactive tool →

GHK-Cu Dosage Reference Table

Common reconstitution for a 50mg vial. Use the GHK-Cu calculator above to generate your specific settings.

Mechanism of Action

GHK-Cu exerts its biological effects through multiple mechanisms: as a chemotactic factor attracting macrophages and mast cells to wound sites, stimulating fibroblasts to synthesize collagen, elastin, glycosaminoglycans, and decorin, and activating superoxide dismutase (SOD) and other antioxidant enzymes. At the molecular level, GHK-Cu regulates over 4,000 human genes—upregulating tissue-repair and anti-inflammatory genes while downregulating genes associated with inflammation, oxidative stress, and cancer progression. The copper (Cu²⁺) ion is an integral part of its activity and cannot be separated from the peptide without loss of function.

Genome-Wide Activity: Reshaping the Transcriptional Landscape

GHK-Cu's most remarkable and pharmacologically unusual property is its ability to regulate expression of large segments of the human genome. Microarray and RNA-sequencing studies have identified GHK-Cu as a regulator of over 4,000 human genes (~31% of the protein-coding genome) at physiologically relevant concentrations. Crucially, the direction of regulation is not random: GHK-Cu consistently upregulates genes related to tissue maintenance, collagen synthesis, anti-inflammatory signaling, and antioxidant defense, while downregulating genes associated with inflammation, oxidative stress, cancer progression (particularly pro-metastatic genes), and cellular senescence pathways. This bidirectional transcriptional reprogramming has been described as a partial reversal of the aged gene-expression signature toward a younger transcriptional state.

Type I and III Collagen, Elastin, and Glycosaminoglycans

At the dermal level, GHK-Cu stimulates fibroblasts to synthesize type I and III collagen—the major structural proteins of the extracellular matrix, which decline with age and are depleted at wound sites. Specifically, GHK-Cu activates the TGF-β1 pathway and downstream Smad2/3 signaling, driving collagen gene transcription in dermal fibroblasts. Parallel stimulation of elastin synthesis restores tissue elasticity, while increased production of glycosaminoglycans (hyaluronic acid, dermatan sulfate, heparan sulfate) replenishes the hydrated matrix scaffold supporting collagen fibrils. In rodent and in vitro wound models, GHK-Cu-treated cultures consistently show higher collagen density, smaller wound area, and greater mechanical strength at the repair site.

GHK-Cu Reconstitution Steps

Storage and Safety Notes

FAQ

Why is properly reconstituted GHK-Cu solution blue?

A properly reconstituted GHK-Cu solution displays a characteristic clear blue color. This coloration is not a contaminant or degradation product—it is the expected optical signature of the Cu²⁺ coordination complex. Divalent copper ions in an octahedral or distorted octahedral ligand field (provided by the imidazole nitrogen of histidine, the α-amino group of glycine and lysine, and water molecules) absorb light in the orange-red region (~600-800 nm) via d-d electronic transitions and transmit blue wavelengths. The blue intensity is proportional to copper concentration, serving as a practical quality indicator. Visual quality check: a correctly prepared GHK-Cu solution should be uniformly clear blue—not cloudy, not colorless, not green. A colorless solution after reconstitution indicates the copper was absent from the lyophilized powder (a manufacturing quality issue) or was chemically displaced. A green discoloration may indicate copper oxidation to Cu⁺ or contamination. In both cases the vial should be set aside and the supplier notified.

How does GHK-Cu differ from BPC-157 for skin research?

Researchers comparing GHK-Cu and BPC-157 for skin and wound-healing models encounter fundamentally different mechanistic profiles. BPC-157 primarily promotes cell migration and vascularization through angiogenesis (VEGF/VEGFR2) and the FAK-paxillin pathway, with strong gastrointestinal cytoprotection as a secondary endpoint. GHK-Cu acts mainly through gene-expression regulation—upregulating the full spectrum of ECM synthesis genes while suppressing inflammation and oxidative stress. In wound models, BPC-157 tends to produce faster initial vascularization; GHK-Cu produces better-arranged collagen architecture and reduced scarring. They are not mechanistic substitutes but complementary tools studying different stages of the tissue-repair cascade.

How to Use This Reference

Each peptide section follows the same five-part structure: a dosage reference table giving concentration and syringe units for three diluent volumes, the mechanism of action as described in the published preclinical literature, a numbered reconstitution protocol, storage limits before and after reconstitution, and the questions that come up most often for that specific compound.

All content is for laboratory research use only and is not medical advice. None of the peptides described here is approved by any regulatory agency for human use, and none of the dosing figures is a human dose. The 20 per-peptide answers on this page complement the 12 general reconstitution questions on the calculator page.